Multiple Myeloma DREAM Challenge

A Crowdsourced Approach to Improve Identification of High-Risk Patients

Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow,1 and worldwide, > 100,000 patients are diagnosed with the disease each year.2 Multiple myeloma remains an incurable disease, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells.1,3

Current treatment guidelines are based on a number of important patient and disease factors, including risk of rapid progression.1,3 There is an urgent need for a precise risk stratification model to assist in therapeutic decision-making, and although progress has been made,3 there remain significant opportunities to improve patient stratification to optimize treatment and to develop new therapies for high-risk patients. To accelerate the development and evaluation of such risk models in MM, a consortium of academic, industry and non-profit organizations formed a DREAM Challenge, a crowd-sourced competition that engages large cross-disciplinary teams of experts to address complex problems in biomedicine and in which over a petabyte of molecular data is being leveraged to enable model development. Celgene is sponsoring this initiative in partnership and with generous contributions from the following partners: Dana-Farber Cancer Institute, DREAM Challenges, Heidelberg University, M2Gen, Moffitt Cancer Center, the Multiple Myeloma Research Foundation, the Myeloma Genome Project, Sage Bionetworks, and the University of Arkansas for Medical Sciences.

To learn more, please visit (may require sign-up)


  1. NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. V3.2017.
  2. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Accessed March 6, 2017.
  3. US National Library of Medicine. PubMed Health. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®). Accessed April 27, 2017.